1YR Stock Overview
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.11 |
| 52 Week High | kr0.33 |
| 52 Week Low | kr0.0001 |
| Beta | 2.6 |
| 1 Month Change | -18.10% |
| 3 Month Change | -11.71% |
| 1 Year Change | -57.33% |
| 3 Year Change | -99.01% |
| 5 Year Change | n/a |
| Change since IPO | -99.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1YR | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -19.2% | -0.4% | 1.9% |
| 1Y | -57.3% | -6.0% | 5.9% |
Return vs Industry: 1YR underperformed the German Medical Equipment industry which returned -6% over the past year.
Return vs Market: 1YR underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 1YR volatility | |
|---|---|
| 1YR Average Weekly Movement | 29.9% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1YR's share price has been volatile over the past 3 months.
Volatility Over Time: 1YR's weekly volatility has decreased from 2369% to 30% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 11 | Jeff Borcherding | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) Fundamentals Summary
| 1YR fundamental statistics | |
|---|---|
| Market cap | €5.90m |
| Earnings (TTM) | -€22.30m |
| Revenue (TTM) | €103.56k |
57.0x
P/S Ratio-0.3x
P/E RatioIs 1YR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1YR income statement (TTM) | |
|---|---|
| Revenue | kr1.21m |
| Cost of Revenue | kr5.64m |
| Gross Profit | -kr4.43m |
| Other Expenses | kr256.30m |
| Earnings | -kr260.73m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -5.76 |
| Gross Margin | -365.98% |
| Net Profit Margin | -21,529.89% |
| Debt/Equity Ratio | 0% |
How did 1YR perform over the long term?
See historical performance and comparison